Benefits exceed risks of newer antidepressant medications in youth--maybe.
March
J S
JS
Division of Neurosciences Medicine, Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina, USA. john.march@duke.edu
Vitiello
B
B
D000293:Adolescent; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects* / Q000627:therapeutic use; D001521:Behavior Therapy; D002648:Child; D002986:Clinical Trials as Topic; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy* / Q000628:therapy; D015990:Placebo Effect; D018570:Risk Assessment; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D013405:Suicide
D018687:Antidepressive Agents, Second-Generation; D017367:Selective Serotonin Reuptake Inhibitors